Streetbeat News

Earnings

ZIM

ZIM Integrated Shipping Services Ltd. reported strong Q4 earnings and announced generous dividends for 2024. However, there is a significant risk of dividend cuts or elimination in 2025 due to cash burn concerns and profit headwinds.

Portfolio Pulse from

March 17, 2025 | 8:45 pm

XOMA

XOMA reported its Q4 and full-year 2024 financial results, highlighting a significant expansion of its royalty and milestone portfolio. The company doubled its portfolio to over 120 royalty assets through five transactions in 2024.

Portfolio Pulse from

March 17, 2025 | 8:45 pm

DMAC

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) released its full year 2024 financial results and provided a business update. The company, focused on treatments for acute ischemic stroke and preeclampsia, will host a conference call on March 18, 2025, to discuss these updates.

Portfolio Pulse from

March 17, 2025 | 8:45 pm

AATC

Autoscope Technologies Corporation (OTCQX: AATC) released its financial results for the quarter and year ending December 31, 2024.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

ACMR

ACM Research (ACMR) has experienced positive earnings estimate revisions recently, indicating potential strength in its stock. The company is also part of a robust industry, which may further support its stock performance.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

GETY

Getty Images Holdings, Inc. reported its financial results for Q4 and the full year 2024, highlighting its performance as a leading global visual content creator and marketplace.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

NCPL

Netcapital Inc. reported its financial results for the third quarter of fiscal year 2025, ending January 31, 2025. The company operates as a digital private capital markets ecosystem.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

ENZ

Enzo Biochem, Inc. reported its financial results for the fiscal second quarter of 2025, showing improvements in revenue, gross margin, and operating profit/loss compared to the previous quarter.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

GYRE

Gyre Therapeutics reported its financial results for Q4 and full year 2024, with significant developments expected in 2025, including data from a Phase 3 trial, commercial launches in China, and a U.S. Phase 2 trial initiation. Revenue guidance for 2025 is set between $118 to $128 million.

Portfolio Pulse from

March 17, 2025 | 8:30 pm

DRMA

Dermata Therapeutics announced its 2024 financial results and provided a corporate update. The company expects to release topline results from its Phase 3 STAR-1 trial for acne treatment by March 2025. Dermata also entered a collaboration with Revance Therapeutics for a new treatment study and raised $2.55 million in a private placement.

Portfolio Pulse from

March 17, 2025 | 8:30 pm